Hamid Soraya
1, Maryam Rameshrad
2, Aram Mokarizadeh
3, Alireza Garjani
2*1 Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran
2 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 Cellular and Molecular Research Center, and Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Abstract
Introduction: Acute
treatment with metformin has a cardio-protective effects by suppression
of inflammatory responses during myocardial infarction (MI) through
activation of AMP-activated protein kinase (AMPK). Neutrophils have a
pivotal role during MI-induced inflammatory responses. Some
anti-inflammatory treatments have decreased cardiac injury and infarct
size in MI. Here we evaluated the effects of chronic pre-treatment with
metformin on myocardial remodeling and neutrophil recruitment after
isoproterenol-induced MI.
Methods:
Male wistar rats were randomly assigned into 6 groups (n=6) of
untreated control, sham, isoproterenol (Iso), and pre-treated orally
with 25, 50, and 100 mg/kg of metformin, twice daily, for 14 days.
Isoproterenol was injected subcutaneously (sc) at 13th and 14th days for
induction of acute MI. Histopathological examinations were done on the
harvested hearts. Number of neutrophils in peripheral blood and their
infiltration to myocardium were evaluated by Gimsa staining and
myeloperoxidase (MPO) assay, respectively.
Results: Histopathological
analysis showed a significant attenuation of isoproterenol-induced
cardiomyocyte necrosis and fibrosis by all three doses of metformin. The
heart to body weight ratio was also decreased with all doses of
metformin. Pre-treatment with metformin in comparison to Iso (MI) group
reduced peripheral neutrophils (p<0.05, p<0.01, and p<0.001 at
25, 50, and 100 mg/kg; respectively) as well as MPO activity (p<0.05
and p<0.01 at 50 and 100 mg/kg, respectively).
Conclusion:
Pre-treatment with metformin decreased post-MI myocardial injuries by
reducing cardiac remodeling and myocardial neutrophil activity. The
results could be explained as a new mechanism for cardio-protective
effect of metformin.